Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

TapImmune Inc (OTCQB:TPIV)

0.575
Delayed Data
As of May 27
 -0.005 / -0.86%
Today’s Change
0.24
Today|||52-Week Range
1.71
-4.17%
Year-to-Date
SECTOR
Consumer Services
INDUSTRY
Other Consumer Services
MARKET CAP
$39.1M

Company Description

TapImmune, Inc. is focusing on immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer. It develops vaccines for breast cancer, colorectal cancer, ovarian cancer and non-small cell lung cancer. The company was founded in 1991 and is headquartered in Jacksonville, FL.

Contact Information

TapImmune, Inc.
50 North Laura Street
Jacksonville Florida 32202
P:(904) 516-5436
Investor Relations:
(206) 504-7267

Employees

Shareholders

Individual stakeholders8.63%
Mutual fund holders--
Other institutional--

Top Executives

Glynn WilsonChairman, CEO, CFO & CAO
Mark ReddishDirector & Vice President-Development